David Margolis

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

The Lancet · 2017 · First of 24 authors · Corresponding · 418 citations

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

New England Journal of Medicine · 2020 · 401 citations